What is SYBX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SYBX?

P/E (TTM) is n/a and 52-week range is $0.54 to $1.87 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SYBX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SYBX?

The company profile lists revenue (TTM) near $3M, net income (TTM) near $-7.32B, EPS (TTM) near $-0.05 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Synlogic Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Winchester, Massachusetts, US, 12.3M shares outstanding, ISIN US87166L2097 when available from company profile and filing metadata.

Synlogic Inc

$SYBX

Health Care · Biotechnology

IR Run Scenarios

$1.10

+0.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. The company is headquartered in Winchester, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2015-09-30. The firm is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The firm's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The firm designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.

Employees

Website

www.synlogictx.com/

IPO

2015-09-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)